<div id="readability-page-1"><div><ul> <li>Ingredion recently reported a softer fourth quarter for fiscal 2025, with revenue down year on year and its third consecutive quarter of net income and EPS declines, while also missing analysts’ EBITDA and adjusted operating income expectations. </li> <li>Soon after these results, President and CEO James P. Zallie was appointed Chairman following the former Chair’s resignation and sold 9,958 shares under a pre-set Rule 10b5-1 plan, sharpening investor attention on the company’s leadership and governance. </li> <li>We’ll now examine how the CEO’s move into the Chair role and related insider selling could influence Ingredion’s investment narrative.</li> </ul><p>Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.</p><h2>Ingredion Investment Narrative Recap</h2><p>To own Ingredion, you need to believe in its role as a supplier of specialty starches and sweeteners to food, beverage and industrial customers, and in its ability to keep shifting toward higher-value, health-focused ingredients. The softer fourth quarter and leadership changes do not appear to alter the near term catalyst of specialty portfolio growth, but they sharpen the biggest current risk around execution in a slower top line and earnings environment.</p> <p>The most relevant recent announcement is James P. Zallie’s move into the Chairman role alongside his ongoing CEO duties, just as Ingredion works through revenue pressure, three straight quarters of net income and EPS declines, and guidance that calls for only modest sales and operating income growth in 2026. This governance change sits directly against existing risks such as weaker demand in legacy products and price or mix headwinds tied to lower input costs.</p> <p>Yet behind the boardroom reshuffle, investors should be aware that...</p> <p>Read the full narrative on Ingredion (it's free!)</p><p>Ingredion's narrative projects $7.8 billion revenue and $696.0 million earnings by 2028.</p><p>Uncover how Ingredion's forecasts yield a $127.00 fair value, a 8% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1a7f8cd8-9cac-4ccd-a420-f17108d97801/chart/quote-price?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1a7f8cd8-9cac-4ccd-a420-f17108d97801/chart/quote-price"/><figcaption>INGR 1-Year Stock Price Chart</figcaption></figure> <p>Four fair value estimates from the Simply Wall St Community span roughly US$127 to US$240 per share, showing how far apart individual views can be. Set against this, ongoing price and mix headwinds in key segments may prove just as important for Ingredion’s performance as any valuation work, so it is worth comparing several of these perspectives before making up your own mind.</p><p>Explore 4 other fair value estimates on Ingredion - why the stock might be worth just $127.00!</p><h2>Decide For Yourself</h2><p>Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your Ingredion research is our analysis highlighting 4 key rewards that could impact your investment decision.</li><li>Our free Ingredion research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ingredion's overall financial health at a glance.</li></ul><h2>Contemplating Other Strategies?</h2><p>Our top stock finds are flying under the radar-for now. Get in early:</p><ul><li>Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.</li><li>AI is about to change healthcare. These 28 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.</li><li>Uncover the next big thing with 30 elite penny stocks that balance risk and reward.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><div><p>• Dividend Powerhouses (3%+ Yield)<br/>• Undervalued Small Caps with Insider Buying<br/>• High growth Tech and AI Companies</p><p>Or build your own from over 50 metrics.</p></div><p>Explore Now for Free</p></div></div></div>

INGR

<p>Ingredion's recent fourth quarter results for fiscal 2025 showed a decline in revenue and net income, missing analysts' expectations. Following these results, CEO James P. Zallie was appointed Chairman and sold nearly 10,000 shares, raising concerns about leadership and governance. Despite these challenges, the company's focus on specialty starches and health-oriented ingredients remains intact. Analysts project a revenue of $7.8 billion and earnings of $696 million by 2028, with a fair value estimate of $127 per share, indicating potential upside. Investors are advised to consider various perspectives before making decisions.</p>

Does CEO Zallie’s New Chairman Role And Share Sale Reshape The Bull Case For Ingredion (INGR)?